Literature DB >> 8587044

Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations.

T Lave1, B Levet-Trafit, A H Schmitt-Hoffmann, B Morgenroth, W Richter, R C Chou.   

Abstract

Interspecies scaling is used to extrapolate pharmacokinetic parameters from animals to humans, through the application of physiologically based models, by empirical allometric procedures, or using concentration-time transformations. The aim of this study was to compare the accuracies of the last two methods for predicting the pharmacokinetic parameters and concentration-time curves in humans. In the first part of this study, interspecies scaling techniques were applied to a hypothetical drug (extracellular distribution and elimination through glomerular filtration), to examine the influence of various laboratory animals (mouse, rat, cynomolgus monkey and dog) on the parameters predicted for man. The same techniques were also applied to interferon-alpha A, using the literature data for various animal species. The kinetic parameters predicted in man were then compared to the values published for man. Our theoretical example showed that, for allometric scaling, each species has a very different influence on the prediction in human. With the approach using concentration-time transformations, however, each animal species potentially makes a similar contribution to the prediction for man. Based on the pharmacokinetic data published for interferon-alpha A in laboratory animals, allometric equations underestimated the observed values of CL and Vdss in man by 2-3-fold, and the prediction of t1/2 was likely to be unreliable, due to a poor correlation. The use of equivalent time, kallynochron, and apolysichron transformations improved the pharmacokinetic predictions for all three parameters in man. In conclusion, concentration-time transformations make more adequate use of the data available in the different species of laboratory animals, to give better predictions of the pharmacokinetic parameters in man.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8587044     DOI: 10.1002/jps.2600841106

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

1.  Allometric scaling of xenobiotic clearance: uncertainty versus universality.

Authors:  T M Hu; W L Hayton
Journal:  AAPS PharmSci       Date:  2001

Review 2.  Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations.

Authors:  T Lavé; P Coassolo; B Reigner
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

3.  Modification of the P-glycoprotein dependent pharmacokinetics of digoxin in rats by human recombinant interferon-alpha.

Authors:  Makrem Ben Reguiga; Laurence Bonhomme-Faivre; Simone Orbach-Arbouys; Robert Farinotti
Journal:  Pharm Res       Date:  2005-08-16       Impact factor: 4.200

4.  Prediction of drug clearance in humans from laboratory animals based on body surface area.

Authors:  X D Liu; J Chen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Oct-Dec       Impact factor: 2.441

5.  Mixed effect modeling of sumatriptan pharmacokinetics during drug development. I: Interspecies allometric scaling.

Authors:  V F Cosson; E Fuseau; C Efthymiopoulos; A Bye
Journal:  J Pharmacokinet Biopharm       Date:  1997-04

6.  Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons.

Authors:  Leonid Kagan; Anson K Abraham; John M Harrold; Donald E Mager
Journal:  Pharm Res       Date:  2010-03-16       Impact factor: 4.200

7.  Fractal volume of drug distribution: it scales proportionally to body mass.

Authors:  V Karalis; L Claret; A Iliadis; P Macheras
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

8.  Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs.

Authors:  Yeamin Huh; David E Smith; Meihau Rose Feng
Journal:  Xenobiotica       Date:  2011-09-05       Impact factor: 1.908

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.